secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001711279-25-000037
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Krystal Biotech Presents Preclinical Data on KB801 Gene Therapy for Neurotrophic Keratitis at ARVO 2025
--------------------------------------------------------------------------------

- KB801 is a topical HSV-1-based vector encoding human NGF for neurotrophic keratitis, disclosed in an 8-K filed May 5, 2025.
- In vitro, KB801 transduction of primary human corneal epithelial cells resulted in dose-dependent secretion of mature, functional NGF protein.
- In a murine corneal wound model, a single topical KB801 dose produced higher peak NGF (491 pg/eye) and prolonged exposure (t1/2 55.5 hrs) vs. rhNGF (t1/2 83 min).
- After eight weekly topical KB801 doses, eyes showed only mild inflammatory infiltrate with no necrosis; all resolved by 27 days post-treatment.
- Poster presented at ARVO 2025 Annual Meeting in Salt Lake City, Utah on May 5, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000037/0001711279-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000037/krys-20250505.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer